Small Doses: News for Pharmacists This week, take a look at studies and news on supplements, depression, opioids, and more. Small doses is the news you need in a way that works for you. New diabetes medications help address linked diseases Experts share updates on new diabetes medications, and provide an overview of what’s coming. FDA approves 2 injectable diabetes drugs November 28, 2016 By Christine Blank Two new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA. Top drivers of diabetes care costs June 19, 2016 By Karen Appold How much does diabetes cost the healthcare system and what's driving cost increases? Find out. Applying telemedicine in diabetes care management April 06, 2016 By Karen Appold Telemedicine could improve diabetic patient outcomes, expand access, and provide better economic value for patients. Find out how. Innovative diabetes cost-reduction strategies April 03, 2016 By Aine Cryts Here are some of the innovative approaches payers and providers are taking to quell the diabetes epidemic, and curb the costs associated with it. Diabetes drug spending on the rise March 31, 2016 By Tracey Walker The sheer volume of diabetes patients has made it a big driver of medication spending. Here are some important formulary considerations. Strategies to reduce diabetes health management costs March 03, 2016 By Karen Appold Rob Danoff, DO, of Aria Health System, explains what should be done to reduce health management costs, while improving care of diabetic patients. Reducing type 2 diabetes mortality: empagliflozin study The results of a large study of the impact of empagliflozin (Jardiance) on cardiovascular outcomes were recently published. Here are some key takeaways. FDA warns of joint pain for DPP-4 diabetes drugs September 02, 2015 By Christine Blank FDA warned this week that several leading drugs for type 2 diabetes may cause severe and disabling joint pain. FDA said that sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain, and added a new Warning and Precaution about this risk to the labels of all dipeptidyl peptidase-4 (DPP-4) inhibitors.